A pilot study of cetuximab and the hedgehog inhibitor IPI-926 in recurrent/metastatic head and neck squamous cell carcinoma

BACKGROUND: This phase 1, dose-finding study determined the safety, maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D), antitumor activity, and molecular correlates of IPI-926, a Hedgehog pathway (HhP) inhibitor, combined with cetuximab in patients with relapsed/metastatic squamous cell ca...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oral Oncol
Main Authors: Bowles, Daniel W., Keysar, Stephen B., Eagles, Justin R., Wang, Guoliang, Glogowska, Magdalena J., McDermott, Jessica D., Le, Phuong N., Gao, Dexiang, Ray, Charles E., Rochon, Paul J., Roop, Dennis R., Tan, Aik-Choon, Serracino, Hilary S., Jimeno, Antonio
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5676309/
https://ncbi.nlm.nih.gov/pubmed/26705064
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.oraloncology.2015.11.014
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados